🔗 Share this article The Global Health Body Issues Warning Over Critical Shortage of Obesity Injections Less than a tenth of patients that would benefit from GLP-1 drugs like Wegovy are able to get them, warns the World Health Organization as it issues its first advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication. Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention. "Our latest guidance acknowledges that obesity is a chronic disease that can be addressed with comprehensive and continuous support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad availability to the injections that can aid individuals in losing significant body mass, says the organization. GLP-1 Therapy Supply Crisis Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, according to the WHO. The advice encourages governments and firms to expand availability, via strategies like licensing agreements. Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026. The Way Obesity Injections Operate The injections mimick a biological compound to slow digestion, suppress the appetite and boost satiety so people reduce food intake. Patients commonly see weight reduction within a few weeks of commencing the weekly injections. Evidence points to people may put most of the weight back on within a year of halting the medication, when their usual food cravings come back. Being above a healthy weight increases your chance for experiencing medical conditions, such as diabetes, heart disease, brain attack, and specific cancers. Obesity concerns people in every country and was linked to millions of fatalities worldwide in 2024, as per the health agency.
Less than a tenth of patients that would benefit from GLP-1 drugs like Wegovy are able to get them, warns the World Health Organization as it issues its first advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication. Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention. "Our latest guidance acknowledges that obesity is a chronic disease that can be addressed with comprehensive and continuous support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad availability to the injections that can aid individuals in losing significant body mass, says the organization. GLP-1 Therapy Supply Crisis Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, according to the WHO. The advice encourages governments and firms to expand availability, via strategies like licensing agreements. Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026. The Way Obesity Injections Operate The injections mimick a biological compound to slow digestion, suppress the appetite and boost satiety so people reduce food intake. Patients commonly see weight reduction within a few weeks of commencing the weekly injections. Evidence points to people may put most of the weight back on within a year of halting the medication, when their usual food cravings come back. Being above a healthy weight increases your chance for experiencing medical conditions, such as diabetes, heart disease, brain attack, and specific cancers. Obesity concerns people in every country and was linked to millions of fatalities worldwide in 2024, as per the health agency.